Mass balance and pharmacokinetics of [ 14C]telavancin following intravenous administration to healthy male volunteers

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3365-3371

  Shaw, Jeng Pyng ^a   Cheong, Jonathan ^a   Goldberg, Michael R ^a   Kitt, Michael M ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; TELAVANCIN; TELAVANCIN C 14; THRX 651540; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSGEUSIA; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; FECES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 77955381767     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01750-09     Document Type: Article

References (19)

1. Barriere, S., F. Genter, E. Spencer, M. Kitt, D. Hoelscher, and J. Morganroth. 2004. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. 44:689-695.
2. Baxter Healthcare Corporation. 2003. Vancocin package insert. Baxter Healthcare Corporation, Deerfield, IL.
3. Davies, B., and T. Morris. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
4. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388.
5. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121.
6. Gotfried, M. H., J. P. Shaw, B. M. Benton, K. M. Krause, M. R. Goldberg, M. M. Kitt, and S. L. Barriere. 2008. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52:92-97.
7. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
8. International Commission on Radiological Protection. 1993. ICRP publication 62: radiological protection in biomedical Research, 62. Pergamon Press, Oxford, United Kingdom.
9. Krause, K. M., M. Renelli, S. Difuntorum, T. X. Wu, D. V. Debabov, and B. M. Benton. 2008. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob. Agents Chemother. 52:2647-2652.
10. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
11. Merck and Co. 2008. Invanz package insert. Merck and Co., Whitehouse Station, NJ.
12. Roffey, S. J., R. S. Obach, J. I. Gedge, and D. A. Smith. 2007. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 39:17-43.
13. Rubinstein, E., G. R. Corey, M. E. Stryjewski, H. W. Boucher, R. N. Daly, F. C. Genter, S. L. Barriere, M. M. Kitt, and H. D. Friedland. 2008. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. Clin. Microbiol. Infect. 14:S14.
14. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
15. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallée, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
16. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
17. Sun, H. K., K. Duchin, C. H. Nightingale, J. P. Shaw, J. Seroogy, and D. P. Nicolau. 2006. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50:788-790.
18. Woodworth, J. R., E. H. Nyhart, Jr., G. L. Brier, J. D. Wolny, and H. R. Black. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. 36:318-325.
19. Wyeth Pharmaceuticals Inc. 2009. Tygacil package insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA.